; Whereas according to the Centers for Disease Control and Prevention, Neisseria meningitidis serogroup B accounts for approximately half of all cases of meningococcal disease among individuals ages 15 to 22 in the United States; Whereas vaccination for serogroups A, C, W, and Y is routinely recommended by the Centers for Disease Control and Prevention; Whereas the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention recommends that decisions to vaccinate adolescents and young adults ages 16 to 23 against the strain of meningococcal disease caused by serogroup B should be made at the individual level with health care providers; Whereas a recent study found that many doctors are not talking to patients about the MenB vaccine, including 49 percent of pediatricians and 69 percent of family physicians who do not regularly discuss the MenB vaccine during routine visits with individuals ages 16 to 18; Whereas meningitis vaccines are covered by public and private health insurance plans, and individuals should be encouraged to contact health insurance plans to determine coverage of MenACWY and MenB vaccines; Whereas the Federal Vaccines for Children program covers both MenACWY and MenB vaccines for— (1) children and adults who have no health insurance or whose health insurance does not cover those vaccines; and (2) children less than 19 years of age who are American Indian, Alaska Native, or eligible for Medicaid or other State health plan coverage; Whereas in 2012, before meningitis B vaccines were available in the United States, Kimberly Coffey, a 17-year-old high school senior on Long Island, New York, died from meningitis B; Whereas Patti Wukovits, R.N., the mother of Kimberly Coffey, created the Kimberly Coffey Foundation, a vital organization with the mission of— (1) providing education to the public and health care professionals about meningococcal disease; and (2) advocating for two types of vaccination for meningococcal disease